Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
Efstathiou, Jason A
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan 2009 - 92-9 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2007.12.3752 doi
Adult
Aged
Antineoplastic Agents, Hormonal--adverse effects
Cardiovascular Diseases--mortality
Goserelin--adverse effects
Humans
Male
Middle Aged
Prostatic Neoplasms--complications
Regression Analysis
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan 2009 - 92-9 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2007.12.3752 doi
Adult
Aged
Antineoplastic Agents, Hormonal--adverse effects
Cardiovascular Diseases--mortality
Goserelin--adverse effects
Humans
Male
Middle Aged
Prostatic Neoplasms--complications
Regression Analysis